Compare Bill.com Holdings Inc (BILL) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bill.com Holdings Inc vs Incyte Corporation — how do they compare? Bill.com Holdings Inc trades at $48.25 (market cap $4.93B), while Incyte Corporation trades at $120.95 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 5× Bill.com Holdings Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Bill.com Holdings Inc nearer its low. Which is the better fit depends on your goals.
| BILL | INCY | |
|---|---|---|
Market Cap | $4.93B | $24.54B |
Sector | Technology | Health |
52-Week High | $56.32 | $129.93 |
52-Week Low | $31.96 | $81.61 |
Enterprise Value | $4.64B | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BILL Holdings trades at $48.37, down 1.81% today, with a bullish technical signal and strong analyst support (56% buy ratings). The company shows improving fundamentals with revenue growth to $1.46B in 2025 and three consecutive quarterly EPS beats, though profitability remains thin with a net margin of 0.01%. Recent news highlights AI-driven strategy and operational efficiency gains.
Outlook is cautiously optimistic given earnings momentum and institutional accumulation, but high valuation (P/E 213.91) and negative cash flow from investing pose risks. Upside to consensus price target $45.67 appears limited at current levels, requiring sustained execution for further gains.
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bill.com Holdings Inc
Bill.com Holdings Inc is a provider of cloud-based software that simplifies, digitizes, and automates financial operations for SMBs. Its artificial-intelligence enabled financial software platform used mostly to build connections between customers, suppliers, and clients. The company's platform generates and process invoices, streamline approvals, send and receive payments, sync with their accounting system, and manage their cash. The firm generates revenue through subscription and transaction fees.
Read more on BILL →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
